Cardiovascular prevention in subjects with impaired fasting glucose or impaired glucose tolerance

High Blood Pressure and Cardiovascular Prevention

Volumn 17, Issue 2, 2010, Pages 73-102

  Volpe, Massimo ^a,b   Borghi, Claudio ^c   Cavallo Perin, Paolo ^d   Chiariello, Massimo ^e   Manzato, Enzo ^f   Miccoli, Roberto ^g   Modena, Maria Grazia ^h   Riccardi, Gabriele ⁱ   Sesti, Giorgio ^j   Tiengo, Antonio ^k   Trimarco, Bruno ^e   Vanuzzo, Diego ^f   Verdecchia, Paolo ^l   Zaninelli, Augusto ^m   Del Prato, Stefano ⁿ  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e Department of Clinical Medicine Cardiovascular Sciences and Immunology ^*  (Italy)

^f UNIVERSITY OF PADOVA   (Italy)

^g UNIVERSITY OF PISA   (Italy)

^h UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

ⁱ UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^j UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^k Centro Per la Prevenzione Cardiovascolare   (Italy)

^l SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^m UNIVERSITY OF FLORENCE   (Italy)

ⁿ CISANELLO HOSPITAL   (Italy)

more..

Author keywords

abnormal glucose regulation; cardiovascular prevention; diabetes mellitus; hypertension; impaired glucose tolerance; insulin resistance; metabolic syndrome

Indexed keywords

ACARBOSE; ACETYLSALICYLIC ACID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EZETIMIBE; FIBRIC ACID DERIVATIVE; GLIBENCLAMIDE; GLICLAZIDE; GLUCOSE; HEMOGLOBIN A1C; INDAPAMIDE; INSULIN; IRBESARTAN; LOSARTAN; METFORMIN; NICOTINIC ACID DERIVATIVE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; RAMIPRIL; RIMONABANT; ROSIGLITAZONE; SULFONYLUREA; TELMISARTAN; TOLBUTAMIDE; TROGLITAZONE; UNINDEXED DRUG; VALSARTAN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ALGORITHM; ANTIHYPERTENSIVE THERAPY; ARTERY DISEASE; AUTONOMIC NEUROPATHY; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DIAGNOSTIC TEST; DIET; DYSLIPIDEMIA; EARLY DIAGNOSIS; EVIDENCE BASED MEDICINE; GENERAL PRACTICE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEALTH CARE PERSONNEL; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMPAIRED FASTING GLUCOSE; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MEDICAL INFORMATION; METABOLIC SYNDROME X; MICROALBUMINURIA; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; PREVENTIVE MEDICINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY TRACT DISEASE; REVIEW; RISK ASSESSMENT; SCREENING TEST; SLEEP APNEA SYNDROME; UNSPECIFIED SIDE EFFECT;

EID: 77955433121     PISSN: 11209879     EISSN: 11791985     Source Type: Journal    
DOI: 10.2165/11311830-000000000-00000     Document Type: Review

References (112)

1. Sesti G, Volpe M, Cosentino F, et al. Metabolic syndrome: diagnosis and clinical management, an Official Document of the Working Group of the Italian Society of Cardiovascular Prevention (SIPREC). High Blood Press Cardiovasc Prev 2006; 13 (4): 185-198
2. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008 Jun 12; 358 (24): 2545-2559
3. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008 Jun 12; 358 (24): 2560-2572
4. Abraira C, Colwell J, Nuttall F, et al. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Arch Intern Med 1997 Jan 27; 157 (2): 181-188
5. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005 Dec 22; 353 (25): 2643-2653
6. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998 Sep 12; 317 (7160):703-713
7. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003 Jan 30; 348 (5): 383-393 (Pubitemid 36159355)
8. Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008 Feb 7; 358 (6): 580-591
9. Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. DECODE Study Group on behalf of the European Diabetes Epidemiology Study Group. BMJ 1998 Aug 8;317 (7155):371-375
10. Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 2006 May; 29 (5): 1130-1139
11. Gerstein HC, Santaguida P, Raina P, et al. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract 2007 Dec; 78 (3): 305-312
12. Nathan DM, Davidson MB, DeFronzo RA, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007 Mar; 30 (3): 753-759
13. Danaei G, Lawes CM, Vander Hoorn S, et al. Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-opti- mum blood glucose concentration: comparative risk assessment. Lancet 2006 Nov 11; 368 (9548): 1651-1659
14. Bartnik M, Norhammar A, Ryden L. Hyperglycaemia and cardiovascular disease. J Intern Med 2007 Aug; 262 (2): 145-156
15. Bianchi C, Miccoli R, Penno G, et al. Primary prevention of cardiovascular disease in people with dysglycemia. Diabetes Care 2008 Feb; 31 Suppl. 2: S208-14
16. Crandall JP, Knowler WC, Kahn SE, et al. The prevention of type 2 diabetes. Nat Clin Pract Endocrinol Metab 2008 Jul; 4 (7): 382-393
17. Standards of medical care in diabetes - 2010. Diabetes Care 2010 Jan; 33 Suppl. 1: S11-61
18. Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007 Jan; 28 (1): 88-136
19. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 2003 Mar; 26 (3): 688-696
20. Vanuzzo D, Pilotto L, Uguccioni M, et al. Cardiovascular epidemiology: trends of risk factors in Italy. Ital Heart J 2004 Nov; 5 Suppl. 8: 19S-27S; discussion 33S-4, 116S-21S
21. Maggi S, Noale M, Gallina P, et al. Metabolic syndrome, diabetes, and cardiovascular disease in an elderly Caucasian cohort: the Italian Longitudinal Study on Aging. J Gerontol A Biol Sci Med Sci 2006 May; 61 (5): 505-510 (Pubitemid 43794711)
22. Mannucci E, Monami M, Rotella CM. How many components for the metabolic syndrome? Results of exploratory factor analysis in the FIBAR study. Nutr Metab Cardiovasc Dis 2007 Dec; 17 (10): 719-726
23. Miccoli R, Bianchi C, Odoguardi L, et al. Prevalence of the metabolic syndrome among Italian adults according to ATP III definition. Nutr Metab Cardiovasc Dis 2005 Aug; 15 (4): 250-254
24. Irace C, Cortese C, Fiaschi E, et al. Components of the metabolic syndrome and carotid atherosclerosis: role of elevated blood pressure. Hypertension 2005 Apr; 45 (4): 597-601
25. Garancini MP, Calori G, Ruotolo G, et al. Prevalence of NIDDM and impaired glucose tolerance in Italy: an OGTT-based population study. Dia- betologia 1995 Mar; 38 (3): 306-313
26. Cicero AF, Dormi A, Nascetti S, et al. Relative role of major risk factors for type 2 diabetes development in the historical cohort of the Brisighella Heart Study: an 8-year follow-up. Diabet Med 2005 Sep; 22 (9): 1263-1266
27. Vaccaro O, Riccardi G. Changing the definition of impaired fasting glucose: impact on the classification of individuals and risk definition. Diabetes Care 2005 Jul; 28 (7): 1786-1788
28. Barbagallo CM, Cavera G, Sapienza M, et al. Prevalence of overweight and obesity in a rural southern Italy population and relationships with total and cardiovascular mortality: the Ventimiglia di Sicilia project. Int J Obes Relat Metab Disord 2001 Feb; 25 (2): 185-190
29. Noto D, Barbagallo CM, Cefalu AB, et al. The metabolic syndrome predicts cardiovascular events in subjects with normal fasting glucose: results of a 15 years follow-up in a Mediterranean population. Atherosclerosis 2008 Mar; 197 (1): 147-153
30. Bonora E, Kiechl S, Willeit J, et al. Population-based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck study. Diabetes 2004 Jul; 53 (7): 1782-1789
31. Vaccaro O, Ruffa G, Imperatore G, et al. Risk of diabetes in the new diagnostic category of impaired fasting glucose: a prospective analysis. Diabetes Care 1999 Sep; 22 (9): 1490-1493
32. Diagnosis and classification of diabetes mellitus. Diabetes Care 2008 Jan; 31 Suppl. 1: S55-60
33. Standards of medical care in diabetes - 2008. Diabetes Care 2008 Jan; 31 Suppl. 1: S12-54
34. Fowler G. The teaching of preventive medicine: the role of the primary health care team. J R Soc Med 1986 Nov; 79 (11): 633-636
35. Lloyd-Jones DM, Larson MG, Beiser A, et al. Lifetime risk of developing coronary heart disease. Lancet 1999 Jan 9; 353 (9147): 89-92
36. Cooper R, Cutler J, Desvigne-Nickens P, et al. Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: findings of the national conference on cardiovascular disease prevention. Circulation 2000 Dec 19; 102 (25): 3137-3147
37. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004 Sep 11-17; 364 (9438): 937-952
38. Verdecchia P, Schillaci G, Borgioni C, et al. Cigarette smoking, ambulatory blood pressure and cardiac hypertrophy in essential hypertension. J Hy- pertens 1995 Oct; 13 (10): 1209-1215
39. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease: overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992 Jan; 152 (1): 56-64
40. Fox CS, Coady S, Sorlie PD, et al. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 2007 Mar 27; 115 (12): 1544-1550
41. Kronmal RA, Barzilay JI, Smith NL, et al. Mortality in pharmacologically treated older adults with diabetes: the Cardiovascular Health Study, 19892001 [abstract]. PLoS Med 2006 Oct; 3 (10): e400
42. Mancia G, Bombelli M, Facchetti R, et al. Long-term risk of diabetes, hypertension and left ventricular hypertrophy associated with the metabolic syndrome in a general population. J Hypertens 2008 Aug; 26 (8): 1602-1611
43. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For End- point reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 Mar 23; 359 (9311): 1004-1010 (Pubitemid 34286537)
44. Verdecchia P, Reboldi G, Angeli F, et al. Prognostic value of lipoprotein fractions in essential hypertension. Blood Press 2004; 13 (5): 295-303
45. Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004 May; 43 (5): 963-969
46. Mancia G, De Backer G, Dominiczak A, et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007 Sep; 25 (9): 1751-1762
47. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo- Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005 Sep 10-16; 366 (9489): 895-906
48. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008 Dec 4; 359 (23): 2417-2428
49. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 Mar 23; 359 (9311): 995-1003 (Pubitemid 34286536)
50. Mochizuki S, DahlofB, Shimizu M, et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007 Apr 28; 369 (9571): 1431-1439
51. McMurray JJ, Holman RR, Haffner SM, et al., NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010; 362 (16): 1477-1490
52. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006 Feb 2; 354 (5): 449-461
53. Suleiman M, Hammerman H, Boulos M, et al. Fasting glucose is an important independent risk factor for 30-day mortality in patients with acute myocardial infarction: a prospective study. Circulation 2005 Feb 15; 111 (6): 754-760
54. Meier JJ, Deifuss S, Klamann A, et al. Plasma glucose at hospital admission and previous metabolic control determine myocardial infarct size and survival in patients with and without type 2 diabetes: the Langendreer Myo- cardial Infarction and Blood Glucose in Diabetic Patients Assessment (LAMBDA). Diabetes Care 2005 Oct; 28 (10): 2551-2553
55. Meier JJ, Deifuss S, Klamann A, et al. Influence of an antidiabetic treatment with sulfonylurea drugs on long-term survival after acute myocardial infarction in patients with type 2 diabetes. The LAngendreer Myocardial infarction and Blood glucose in Diabetic patients Assessment (LAMBDA). Exp Clin Endocrinol Diabetes 2003 Sep; 111 (6): 344-350
56. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008 Apr 10; 358 (15): 1547-1559
57. Deedwania P, Kosiborod M, Barrett E, et al. Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2008 Mar 25; 117 (12): 1610-1619
58. Malmberg K. Prospective randomised study ofintensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 1997 May 24; 314 (7093): 1512-1515
59. Walter RE, Beiser A, Givelber RJ, et al. Association between glycemic state and lung function: the Framingham Heart Study. Am J Respir Crit Care Med 2003 Mar 15; 167 (6): 911-916
60. Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 2007 Apr; 191 (2): 235-240 (Pubitemid 46400718)
61. Hu FB, Stampfer MJ, Haffner SM, et al. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 2002 Jul; 25 (7): 1129-1134
62. Schupp M, Janke J, Clasen R, et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004 May 4; 109 (17): 2054-2057
63. Ceriello A, Assaloni R, Da Ros R, et al. Effect of irbesartan on nitrotyrosine generation in non-hypertensive diabetic patients. Diabetologia 2004 Sep; 47 (9): 1535-1540
64. Norhammar A, Malmberg K, Diderholm E, et al. Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration ofthe extent of coronary artery disease and benefits of revascularization. J Am Coll Cardiol 2004 Feb 18; 43 (4): 585-591
65. Kotliar C, Forcada P, Ferdinand KC. Noninvasive diagnosis of subclinical atherosclerosis in cardiometabolic syndrome: a call to action. J Cardiometab Syndr 2008 Winter; 3 (1): 60-62
66. Lloyd-Jones DM, Wilson PW, Larson MG, et al. Framingham risk score and prediction of lifetime risk for coronary heart disease. Am J Cardiol 2004 Jul 1; 94 (1): 20-24
67. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003 Jun; 24(11): 987-1003
68. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Peripheral Arterial Disease) - endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006 Mar 21; 113 (11): e463-654
69. American Diabetes Association. Consensus development conference on the diagnosis of coronary heart disease in people with diabetes; 10-11 February 1998, Miami, Florida. Diabetes Care 1998 Sep; 21 (9): 1551-1559
70. Scholte AJ, Schuijf JD, Kharagjitsingh AV, et al. Prevalence of coronary artery disease and plaque morphology assessed by multi-slice computed tomography coronary angiography and calcium scoring in asymptomatic patients with type 2 diabetes. Heart 2008 Mar; 94 (3): 290-295
71. Shaw LJ, Berman DS, Blumenthal RS, et al. Clinical imaging for prevention: directed strategies for improved detection of presymptomatic patients with undetected atherosclerosis - part I: clinical imaging for prevention. J Nucl Cardiol 2008 Jan-Feb; 15 (1): e6-19
72. Wackers FJ, Chyun DA, Young LH, et al. Resolution of asymptomatic myocardial ischemia in patients with type 2 diabetes in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) study. Diabetes Care 2007 Nov; 30 (11): 2892-2898
73. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004 Aug 21-27; 364 (9435): 685-696
74. Maron DJ, Boden WE, O'Rourke RA, et al. Intensive multifactorial intervention for stable coronary artery disease: optimal medical therapy in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial. J Am Coll Cardiol 2010 Mar 30; 55 (13): 1348-1358
75. Rutter MK, Nesto RW. The BARI 2D study: a randomised trial of therapies for type 2 diabetes and coronary artery disease. Diab Vasc Dis Res 2010 Jan; 7 (1): 69-72
76. Poli A, Marangoni F, Paoletti R, et al. Non-pharmacological control of plasma cholesterol levels. Nutr Metab Cardiovasc Dis 2008 Feb; 18 (2): S1-16
77. Riccardi G, Rivellese AA, Giacco R. Role of glycemic index and glycemic load in the healthy state, in prediabetes, and in diabetes. Am J Clin Nutr 2008 Jan; 87 (1): 269S-74S
78. Mann JI, De Leeuw I, Hermansen K, et al. Evidence-based nutritional approaches to the treatment and prevention of diabetes mellitus. Nutr Metab Cardiovasc Dis 2004 Dec; 14 (6): 373-394
79. Eriksson KF, Lindgarde F. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise: the 6-year Malmo feasibility study. Diabetologia 1991 Dec; 34 (12): 891-898
80. Knowler WC, Sartor G, Melander A, et al. Glucose tolerance and mortality, including a substudy of tolbutamide treatment. Diabetologia 1997 Jun; 40 (6): 680-686
81. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002 Feb 7; 346 (6): 393-403
82. Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002 Jun 15; 359 (9323): 2072-2077
83. Bosch J, Yusuf S, Gerstein HC, et al. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006 Oct 12; 355 (15): 1551-1562
84. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000 Jan 22;355 (9200):253-259
85. YusufS, Sleight P, Pogue J, et al. Effects ofan angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000 Jan 20; 342 (3): 145-153
86. Gerstein HC, Bosch J, Pogue J, et al. Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes: the MICRO-HOPE study - micro- albuminuria, cardiovascular, and renal outcomes. Heart Outcomes Prevention Evaluation. Diabetes Care 1996 Nov; 19 (11): 1225-1228
87. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008 Oct 9; 359 (15): 1577-1589
88. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005 Oct 8; 366 (9493): 1279-1289
89. Viberti G, Kahn SE, Greene DA, et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 2002 Oct; 25 (10): 1737-1743
90. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia 2005 Sep; 48 (9): 1726-1735
91. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes: an interim analysis. N Engl J Med 2007 Jul 5; 357 (1): 28-38
92. Scheen AJ, Finer N, Hollander P, et al. Efficacy and tolerability of rimona- bant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006 Nov 11; 368 (9548): 1660-1672
93. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004 Mar 3; 291 (9): 1071-1080 (Pubitemid 38541684)
94. Malmberg K, Ryden L, Wedel H, et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005 Apr; 26 (7): 650-661
95. Mellbin LG, Malmberg K, Norhammar A, et al. The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Eur Heart J 2008 Jan; 29 (2): 166-176
96. Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008 Jan 12; 371 (9607): 117-125
97. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management ofthe metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005 Oct 25; 112 (17): 2735-2752
98. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002 Dec 14; 360 (9349): 1903-1913
99. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003 Nov 8; 362 (9395): 1527-1535
100. Thomas F, Bean K, Pannier B, et al. Cardiovascular mortality in overweight subjects: the key role of associated risk factors. Hypertension 2005 Oct; 46 (4): 654-659
101. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007 Jan 20; 369 (9557): 201-207
102. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development ofdiabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001 Sep 20; 345 (12): 870-878
103. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001 Sep 20; 345 (12): 851-860
104. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001 Sep 20; 345 (12): 861-869
105. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002 Aug 6; 106 (6): 672-678
106. Sowers JR. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 2004 May; 286 (5): H1597-602
107. Kintscher U, Bramlage P, Paar WD, et al. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey: prospective observational, two armed study in 14,200 patients. Cardiovasc Diabetol 2007; 6: 12-18
108. Vecchione C, Patrucco E, Marino G, et al. Protection from angiotensin II- mediated vasculotoxic and hypertensive response in mice lacking PI3K- gamma. J Exp Med 2005 Apr 18; 201 (8): 1217-1228
109. Chiarelli F, Di Marzio D, Santilli F, et al. Effects of irbesartan on intracellular antioxidant enzyme expression and activity in adolescents and young adults with early diabetic angiopathy. Diabetes Care 2005 Jul; 28 (7): 1690-1697
110. Harris R, Donahue K, Rathore SS, et al. Screening adults for type 2 diabetes: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2003 Feb 4; 138 (3): 215-229
111. Manson JE, Skerrett PJ, Greenland P, et al. The escalating pandemics of obesity and sedentary lifestyle: A call to action for clinicians. Arch Intern Med 2004 Feb 9; 164 (3): 249-258
112. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007 Jan 2; 115 (1): 114-126